OCX +62% Up on no news. A microcap medtech, develops diagnostic tests for early treatment of cancer. Diagnostic companies are usually good shorts.
GALT +25% Up on announcement of deciding with teh FDA for a ph 3 trial for NASH drug, and submitted an app for breakthrough therapy designation for cancer drug. Ph 1 showed good results for cancer therapies.
NTN +22% Provides interactive entertainment and dining technology to bars and restaurants in the US and Canada. Is a nanocap. Up on no news.
UNT +21% Oil and nat gas drilling company in the US.
ZN +20% Up likely from a short squeeze, every short covering at once bc the company is fighting back against SEC investigation allegations, and continues to promote itself.
TITN +19% Beat revs and earns. Inc guidance. PT raised by Craig Hallum to $26 from $24.
CDMO +18% A microcap manufacturer of biopharma products. Up on no news.
MOV +16% Up on earnings beat, inc div.
SHSP +15% Up on the issuance of promissory notes. Is a microcap cloud based marketing tech company. Up on being able to issue promissory notes in a private placement.
SPB +15% There's the expiration of a waiting period, so that means the merger with Energizer will likely go through in the US.
HRG +15% Midcap company, no apparent news.
CARG +14% Hit 52 week high, got a buy rating from Benchmark analyst.
FOMX +14% Average volume. Clinical stage bio company, develops foam-based formulations primarily to treat acne and other skin conditions.
NPTN +14% Northland analyst said should get acquired soon on 3/27. Took 2 days for the stock to react to that analyst's comment.
VRNT +14% Q4 earnings beat, PT raised to $50 by RBC.
SITO +13% Reversal from 2 day downtrend, no news. Stock quite a bit lower from its earnings miss on 3/21.
LFIN -49% Got slammed from fraud accusations, getting removed from the index, and Citron tweet.
FWP -22% Biotech company from Denmark. No apparent news.
MARK -20% Reported bigger than expected loss.
ACXM -19% Down on discontinued partnership with Facebook. Stephens cut PT to $32 from $35. Closed at $23.
MNOV -15% Down on ph2 tiral of MN-166 didn't meet primary endpoint. NASH trial of MN-001 terminated on positive results, will accelerate development.
AKCA -13% Pullback from high point on 3/23.
QHC -13% Down on cautious mention in SA article. Is short, said there's downside risk.
GNMX -11% Normal volume, no news.
CLWT -11% $5M market cap Chinese company, distributes treatment equipment, test kits and supplies.
GME -11% Down on bad guidance. Lots of analyst dgs, some to only $11.
LBY -10% Reached 52 week low. Is a home furnishings company. Company has $380M in debt, could be in trouble.
CLD -9% Dg from natural gas price lowered, is a coal company.